Call for Abstract
11th International Conference on Vascular Dementia, will be organized around the theme “Decoding Dementia and Alzheimer”
Vascular Dementia 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Vascular Dementia 2019
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Dementia is not a specific disease. It's an overall term that describes a wide range of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities. Alzheimer's disease. Vascular dementia, which occurs after a stroke, is the second most common dementia type. But there are many other conditions that can cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. Dementia is a syndrome that involves severe loss of cognitive abilities as a result of disease or injury. Dementia caused by traumatic brain injury is often static, whereas dementia caused by neurodegenerative disorders, such as Alzheimer's disease, is usually progressive and can eventually be fatal.
- Track 1-1Mixed dementia
- Track 1-2Frontotemporal dementia
- Track 1-3Neurogenesis in dementia
- Track 1-4Global prevalence of dementia
- Track 1-5Signs and symptoms of dementia
- Track 1-6Primary mental health care and nursing
- Track 1-7Novel therapeutics technology
- Track 1-8Novel therapeutics strategies for Dementia
Vascular dementia is the broad term for dementia associated with problems of circulation of blood to the brain. There are a number of different types of Vascular dementia. Two of the most common are Multi-infarct dementia and Binswanger's disease. The multi-infarct dementia (MID) and vascular intellectual impedance is dementia caused by issues in the supply of blood to the mind, normally a progression of minor strokes. People with vascular dementia give dynamic subjective hindrance, intensely or sub acutely as in mellow psychological debilitation, every now and again step-wise, after various cerebrovascular occasions (strokes). A few people may seem to enhance amongst occasions and decrease after more noiseless strokes. A quickly decaying condition may prompt demise from a stroke, coronary illness, or infection. Vascular dementia can be caused by ischemic or hemorrhagic infarcts influencing numerous mind regions, including the foremost cerebral supply route domain, the parietal projections, or the cingulate gurus.
- Track 2-1Vascular dementia prognosis
- Track 2-2Young onset dementia
- Track 2-3Multi-infarct dementia
- Track 2-4Parkinson dementia
- Track 2-5Advences in vascular dementia therapy
Lewy body is also known as dementia with Lewy bodies, with Lewy body dementia is the second most common type of progressive dementia after Alzheimer's disease dementia. Protein deposits, called Lewy bodies, develop in nerve cells in the brain regions involved in thinking, memory and movement (motor control).
Lewy body dementia is also causes a progressive decline in mental abilities. The people with Lewy body dementia may experience visual hallucinations and changes in the alertness and attention and other effects include Parkinson's disease-like symptoms such as rigid muscles, slow movement and tremors.
- Track 3-1Risk factor of vascular dementia
- Track 3-2Antipsychotic medications
- Track 3-3Antipsychotic medications
- Track 3-4Palliative care in vascular dementia
- Track 3-5Autophagy
- Track 3-6Synucleinopathies
- Track 4-1Cerebral amyloid angiopathy
- Track 4-2Normal pressure hydrocephalus
- Track 4-3FDG-PET
- Track 4-4Amyloid Immunotherapy
- Track 4-5Beta amyloid protein
Alzheimer's disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. AD begins slowly. It first involves the parts of the brain that control thought, memory and language. People with AD may have trouble remembering things that happened recently or names of people they know. A related problem, mild cognitive impairment (MCI), causes more memory problems than normal for people of the same age. Many, but not all, people with MCI will develop AD.
- Track 5-1Stages of alzheimers
- Track 5-2Diagnosis of alzheimers
- Track 5-3Risk factors of alzheimers
- Track 5-4Clinical studies of alzheimers
- Track 5-5Treatments of alzheimers
Neurodegenerative disease is an umbrella term for a range of conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Examples of neurodegenerative diseases include Parkinson’s, Alzheimer’s, and Huntington’s disease.
- Track 6-1Stroke
- Track 6-2Spinal muscular atrophy (SMA)
- Track 6-3Spinocerebellar ataxia (SCA)
- Track 6-4Huntington’s disease (HD)
- Track 6-5Motor neurone diseases (MND)
- Track 6-6Prion disease
- Track 6-7Parkinson’s disease (PD) and PD-related disorders
- Track 6-8Traumatic brain injury: TBI
- Track 6-9Brain Injury
- Track 6-10Epilepsy
- Track 7-1Migraine
- Track 7-2Attention deficit hyperactivity disorder
- Track 7-3Motor neuron disease
- Track 7-4Bipolar disorder
- Track 7-5Arteriovenous malformation.
- Track 7-6Encephalitis
- Track 7-7Seizures
- Track 7-8Trauma
- Track 7-9Brain abscess
Almost 42% of people over the age of 64 experience some form of memory loss. When there is no underlying medical condition causing this memory loss, it is known as "age-associated memory impairment," which is considered a part of the normal aging process.
- Track 8-1Neuro-anatomical changes in ageing
- Track 8-2Risk factors of cognitive decline
- Track 8-3Granulovacuolar degeneration
- Track 8-4Changes in cerebral cortical microvasculature
- Track 8-5Advances of research in ageing and dementia
The developing number of Dementia patients prompts both approach, monetary and wellbeing association imperatives. Numerous social insurance frameworks have created case administration programs with a specific end goal to advance Alzheimer's patients and guardians care and administrations conveyance. Treatment of dementia relies on upon its cause. On account of most dynamic dementia, including Alzheimer's disease there is no cure and no treatment that moderates or stops its movement. In any case, there are medicating medicines that may briefly enhance side effects. Similar pharmaceuticals used to treat Alzheimer's are among the medications once in a while endorsed to help with side effects of different sorts of dementia. Non-sedate treatments can likewise reduce a few manifestations of Dementia.
- Track 9-1Advances in dementia care management
- Track 9-2Dementia care management program
- Track 9-3Undernutrition and obesity in dementia
- Track 9-4Advance care planning
Caregivers of dementia patients need to understand dementia so that they can understand what the patient is going through. They need to know about underlying diseases, and how these may affect the progress of dementia. They also need to know what sort of behavior to expect. Understanding these helps them plan for their caregiving and to cope with the situation effectively, and with less stress.
- Track 10-1Dementia nursing care plan
- Track 10-2Music therapy in dementia
- Track 10-3Physiotherapy for dementia
- Track 10-4Clinical features of dementia
- Track 10-5Therapeutic interventions in dementia
Treatment of dementia begins with the treatment of the underlying disease, where possible. The underlying causes of nutritional, hormonal, tumour-caused or drug-related dementia may be reversible to some extent. For many other diseases, such as Alzheimer's disease (AD), no cure has yet been discovered. However, improvement of cognitive and behavioural symptoms can be achieved through a combination of appropriate medications and other treatments, including psychotherapy.
- Track 11-1Psychopharmacological treatment
- Track 11-2Advanced drugs for dementia
- Track 11-3Cognitive behavioral therapy
- Track 11-4Family therapy in nursing
Neuropharmacology is an extremely wide locale of science that includes numerous parts of the sensory system from single neuron control to whole ranges of the cerebrum, spinal line, and fringe nerves. To better comprehend the premise behind medication advancement, one should first see how neurons speak with each other. This article will concentrate on both behavioral and atomic neuropharmacology; the real receptors, particle channels, and neurotransmitters controlled through medication activity and how individuals with a neurological issue advantage from this medication activity.
- Track 12-1Neuroscience and neuropharmacology
- Track 12-2Neurochemical interaction
- Track 12-3Molecular neuropharmacology
- Track 12-4Behavioral neuropharmacology
- Track 12-5Advance research in neuropharmacology
The purpose of the session is to consider the use of novel therapeutics for the treatment of dementia and Neurological disorders, Multiple Sclerosis etc. Novel therapeutics includes use of nanotechnology to treat Neurological disorders and CNS disorders and molecular therapeutics based diagnosis etc.
- Track 13-1Novel therapeutics strategies for Dementia
- Track 13-2Novel therapeutics technology
- Track 13-3Novel therapeutics molecule
- Track 13-4Anti-dementia drugs
- Track 13-5Novel drug target for the treatment of dementia
The animal models of Dementia and Alzheimer's diseasefor pre-clinical testing and clinical translation. Dementia is a clinical syndrome with abnormal degree of memory loss and impaired ability to recall events from the past often characterized by Alzheimer's disease.
- Track 14-1Animal models of human cognitive aging
- Track 14-2Genetics of translational models
- Track 14-3Protein-protein interactions
- Track 14-4Pre-clinical testing and clinical translation
- Track 14-5Neurobehavioral Toxicology Testing
It is a branch of Medical Sciences majorly deals with Neuro tumors. Deals with Studies related to Brain and Spinal cord neoplasms. Neuro-oncology and Pediatric Neuro-oncology are the two different Concepts that differentiate the determining methodology of Neuro tumors. Neuro-oncology mainly includes especially related topics like Radiation therapy, Neurosurgery, Neuroimaging, social, Psychological, Neuropathology and psychiatric aspects.
- Track 15-1Spine Cancer and Spine Cancer Treatment
- Track 15-2Risk Factors
- Track 15-3Neurotoxicity
- Track 15-4Astrocytoma
- Track 15-5Pediatric Neuro Oncology
- Track 15-6Malignant Brain Cancers and Brain Metastasis
- Track 15-7Brain Stem Tumors
- Track 15-8Meningioma
- Track 15-9Glioblastoma
- Track 15-10Radiation Therapy And Chemotherapy